Literature DB >> 24090564

Bevacizumab in HIV-positive patients: concerns about safety and potential for therapeutic use.

Nicolas Magné, Cyrus Chargari, Antonin Levy, Jean-Baptiste Guy, Yacine Merrouche, Jean-Philippe Spano.   

Abstract

Human immunodeficiency virus (HIV) patients have more aggressive presentation of colorectal cancer (CRC) and less favourable outcome. Bevacizumab is an antiangiogenic agent that has emerged as a major drug for metastatic CRC. However, few data are available on the safety of bevacizumab in HIV patients. In the light of a case study, we briefly draw intention on how angiogenesis inhibitors could interact with antiviral tri-therapy.

Entities:  

Keywords:  AIDS,; Bevacizumab,; Targeted therapies,; Toxicity

Mesh：

Substances：

Year:  2013        PMID： 24090564     DOI： 10.1179/1973947813Y.0000000109

Source DB:  PubMed          Journal:  J Chemother        ISSN： 1120-009X            Impact factor:   1.714


  15 in total

Review 1.  Inhibitors of angiogenesis: new hopes for oncologists, new challenges for anesthesiologists.

Authors:  Nicolas Libert; Jean-Pierre Tourtier; Lionel Védrine; Cyrus Chargari
Journal:  Anesthesiology       Date:  2010-09       Impact factor: 7.892

2.  Bevacizumab-induced cardiovascular events: a consequence of cholesterol emboli syndrome?

Authors:  Olivier Mir; Luc Mouthon; Jérôme Alexandre; Jean-Michel Mallion; Gilbert Deray; Loïc Guillevin; François Goldwasser
Journal:  J Natl Cancer Inst       Date:  2007-01-03       Impact factor: 13.506

Review 3.  AIDS-related malignancies: state of the art and therapeutic challenges.

Authors:  Jean-Philippe Spano; Dominique Costagliola; Christine Katlama; Nicolas Mounier; Eric Oksenhendler; David Khayat
Journal:  J Clin Oncol       Date:  2008-06-30       Impact factor: 44.544

4.  The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study.

Authors:  Emilie Lanoy; Jean-Philippe Spano; Fabrice Bonnet; Marguerite Guiguet; François Boué; Jacques Cadranel; Guislaine Carcelain; Louis-Jean Couderc; Pierre Frange; Pierre-Marie Girard; Eric Oksenhendler; Isabelle Poizot-Martin; Caroline Semaille; Henri Agut; Christine Katlama; Dominique Costagliola
Journal:  Int J Cancer       Date:  2011-04-27       Impact factor: 7.396

5.  High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy.

Authors:  Kristin E Mondy; John Gottdiener; E Turner Overton; Keith Henry; Tim Bush; Lois Conley; John Hammer; Charles C Carpenter; Erna Kojic; Pragna Patel; John T Brooks
Journal:  Clin Infect Dis       Date:  2010-12-09       Impact factor: 9.079

6.  Colorectal cancer in HIV-infected patients: a case control study.

Authors:  Nir Wasserberg; Joseph W Nunoo-Mensah; Claudia Gonzalez-Ruiz; Robert W Beart; Andreas M Kaiser
Journal:  Int J Colorectal Dis       Date:  2007-02-21       Impact factor: 2.571

7.  Bevacizumab plus irinotecan-, fluorouracil-, and leucovorin-based chemotherapy with concomitant HAART in an HIV-positive patient with metastatic colorectal cancer.

Authors:  Massimiliano Berretta; Arben Lleshi; Ernesto Zanet; Alessandra Bearz; Cecilia Simonelli; Rossella Fisichella; Guglielmo Nasti; Salvatore Berretta; Umberto Tirelli
Journal:  Onkologie       Date:  2008-06-16

8.  First-time use of bevacizumab for aggressive, metastatic hepatocellular carcinoma in an HIV/hepatitis B virus coinfected patient: a case report.

Authors:  Ioannis G Baraboutis; Vassilios Papastamopoulos; Georgios Charitsis; Lazaros J Lekakis; Michael M Vaslamatzis; Athanasios T Skoutelis
Journal:  Eur J Gastroenterol Hepatol       Date:  2008-05       Impact factor: 2.566

Review 9.  Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.

Authors:  Shobha Rani Nalluri; David Chu; Roger Keresztes; Xiaolei Zhu; Shenhong Wu
Journal:  JAMA       Date:  2008-11-19       Impact factor: 56.272

10.  Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion.

Authors:  Colette Smit; Ronald Geskus; Sarah Walker; Caroline Sabin; Roel Coutinho; Kholoud Porter; Maria Prins
Journal:  AIDS       Date:  2006-03-21       Impact factor: 4.177
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.